Effect of atorvastatin on serum omentin-1 in patients with coronary artery disease

Coronary Artery Disease

Volumn 28, Issue 1, 2017, Pages 44-51

  Chen, Qianqian ^a   Shang, Xingchen ^a   Yuan, Meng ^a   Liang, Lining ^a   Zhong, Xia ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

adipokine; atorvastatin; coronary artery disease; omentin 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMENTIN 1 PROTEIN; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ACUTE CORONARY SYNDROME; ANGINA, STABLE; BLOOD; CHINA; DOSE RESPONSE; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; ATORVASTATIN CALCIUM; CHINA; CORONARY ARTERY DISEASE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LECTINS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84991493110     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000435     Document Type: Article

References (63)

1. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-E1261
2. Lis I, Pilarski L, Bogdanski P. Omentin-A newly-discovered adipocytokine in insulin resistance pathogenesis. Pol Merkur Lekarski 2015; 39: 56-60
3. De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661
4. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29-33
5. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013; 98: E514-E517
6. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011; 32: 873-878
7. Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014; 12: 136-143
8. Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama TA, et al. Counteractive effects of omentin-1 against atherogenesisdagger. Cardiovasc Res 2016; 110: 118-128
9. McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study. Curr Pharm Des 2014; 20: 1156-1160
10. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clin Nephrol 2014; 81: 75-85
11. Dursun S, Cuhadar S, Koseoglu M, Atay A, Gunden Aktas S. The antiinflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta. Anadolu Kardiyol Derg 2014; 14: 229-233
12. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005; 5: 122-128
13. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
14. Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, et al. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. Clin Chim Acta 2007; 383: 97-102
15. Yaturu S, Daberry RP, Rains J, Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006; 34: 219-223
16. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71: 202-207
17. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an antiinflammatory role through inhibition of TNF-Alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116-123
18. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-Term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 1139-1147
19. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772
20. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009; 10: 269-279
21. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-Kozani Study. Transl Res 2010; 155: 238-246
22. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; 2010: 535918
23. Tan BK, Pua S, Syed F, Lewandowski KC, O?Hare JP, Randeva HS. Decreased plasma omentin-1 levels in type 1 diabetes mellitus. Diabet Med 2008; 25: 1254-1255
24. Urbanova M, Dostalova I, Trachta P, Drapalova J, Kavalkova P, Haluzikova D, et al. Serum concentrations and subcutaneous adipose tissue mRNA expression of omentin in morbid obesity and type 2 diabetes mellitus: the effect of very-low-calorie diet, physical activity and laparoscopic sleeve gastrectomy. Physiol Res 2014; 63: 207-218
25. Uyeturk U, Sarici H, Kin Tekce B, Eroglu M, Kemahli E, Uyeturk U, et al. Serum omentin level in patients with prostate cancer. Med Oncol 2014; 31: 923
26. Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Syndr 2014; 6: 4
27. Turan H, Yaykasli KO, Soguktas H, Yaykasli E, Aliagaoglu C, Erdem T, et al. Omentin serum levels and omentin gene Val109Asp polymorphism in patients with psoriasis. Int J Dermatol 2014; 53: 601-605
28. Kurt OK, Tosun M, Alcelik A, Yilmaz B, Talay F. Serum omentin levels in patients with obstructive sleep apnea. Sleep Breath 2014; 18: 391-395
29. Onur I, Oz F, Yildiz S, Oflaz H, Sigirci S, Elitok A, et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology 2014; 65: 896-900
30. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011; 16: 657-662
31. Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol 2014; 13: 84
32. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013; 8: e59697
33. Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, et al. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief 2016; 6: 158-161
34. Kadoglou NP, Tahmatzidis DK, Giannakoulas C, Kapelouzou A, Gkontopoulos A, Parissis J, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: Kozani Study. J Cardiovasc Med (Hagerstown) 2015; 16: 341-346
35. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011; 19: 1552-1559
36. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011; 10: 103
37. Xie H, Xie PL, Wu XP, Chen SM, Zhou HD, Yuan LQ, et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res 2011; 92: 296-306
38. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
39. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143
40. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemiainduced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012; 287: 408-417
41. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339-343
42. Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-Alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem Biophys Res Commun 2012; 425: 401-406
43. Uemura Y, Shibata R, Kanemura N, Ohashi K, Kambara T, Hiramatsu-Ito M, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. FASEB J 2015; 29: 141-151
44. Hiramatsu-Ito M, Shibata R, Ohashi K, Uemura Y, Kanemura N, Kambara T, et al. Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice. Cardiovasc Res 2016; 110: 107-117
45. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-III43
46. Waters DD. Exploring new indications for statins beyond atherosclerosis: successes and setbacks. J Cardiol 2010; 55: 155-162
47. Miura S, Saku K. Effects of statin and lipoprotein metabolism in heart failure. J Cardiol 2010; 55: 287-290
48. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904
49. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-491
50. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY, et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008; 32: 810-815
51. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004; 58: 303-309
52. Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab 2013; 98: 4798-4807
53. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681-1684
54. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881-1892
55. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-Type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126: 1205-1213
56. Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM. The peroxisome proliferator-Activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial. J Diabetes Complications 2014; 28: 323-327
57. Ando H, Sugimoto K, Yanagihara H, Tsuruoka S, Saito T, Takamura T, et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008; 35: 1012-1017
58. Bonsu KO, Reidpath DD, Kadirvelu A. Effects of statin treatment on inflammation and cardiac function in heart failure: an adjusted indirect comparison meta-Analysis of randomized trials. Cardiovasc Ther 2015; 33: 338-346
59. Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 2010; 15: 167-174
60. Kaya C, Pabuccu R, Cengiz SD, Dunder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 2010; 118: 161-166
61. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483-490
62. Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010; 25: 27-35
63. Madhu SV, Aslam M, Galav V, Bhattacharya SK, Jafri AA. Atorvastatin prevents type 2 diabetes mellitus-An experimental study. Eur J Pharmacol 2014; 728: 135-140